Guideline Concordance of Testing for Hyperkalemia and Kidney Dysfunction During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure
Why the study?
Does laboratory monitoring for hyperkalemia and kidney dysfunction align with guideline recommendations in patients with HFrEF initiated on MRA therapy?
Population
490 patients hospitalized for heart failure with reduced ejection fraction who were subsequently initiated…
Design
Cohort
Follow-up
30 days
Authors
Discussion
Loading...
Member takes
Implication
Frequent potassium monitoring lapses after MRA initiation in HFrEF warrant caution; leaves open whether targeted interventions improve adherence and outcomes.
Structured PICO
Does laboratory monitoring for hyperkalemia and kidney dysfunction align with guideline recommendations in patients with HFrEF initiated on MRA therapy?
P
Population
490 patients hospitalized for heart failure with reduced ejection fraction who were subsequently initiated on MRA therapy, median age 73 years, 37.1% women.
I
Intervention
Mineralocorticoid receptor antagonist (MRA) therapy initiation (99.4% spironolactone)
O
Outcome
Guideline concordance of testing for hyperkalemia and kidney dysfunction (measurement of serum potassium and creatinine before and after MRA initiation)safety
Laboratory monitoring after MRA initiation in HFrEF patients frequently fails to meet guideline recommendations, highlighting a significant gap in safety monitoring.
Cite This Study
Allen et al. (2013) studied this question.